Related Experiment Video
Updated: Jul 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Left Atrial Appendage Closure: A Single-Center Experience in a Population With a High Prevalence of End-Stage Renal
Luis A Areiza1, Juan F Rodriguez1, David Rodriguez1
1Interventional Cardiology Department, Hospital Universitario Mayor Méderi, Bogotá, D.C., COL.
Insights
Left atrial appendage closure (LAAC) is safe and effective for reducing stroke risk in nonvalvular atrial fibrillation patients, including those on dialysis. This study highlights its feasibility in a Hispanic population.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Left atrial appendage closure (LAAC) offers an alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation (NVAF).
- Existing LAAC data often underrepresents Hispanic populations, limiting understanding of its use in this demographic.
- This study addresses the need for data on LAAC in a Hispanic cohort.
Purpose of the Study:
- To describe the demographic, clinical, and procedural characteristics of Hispanic patients undergoing LAAC.
- To evaluate the safety and efficacy of LAAC in this specific population.
- To assess outcomes in patients with end-stage renal disease on dialysis.
Main Methods:
- Retrospective analysis of adult patients undergoing percutaneous LAAC from June 2017 to July 2022.
- Inclusion of baseline and procedural data.
- Assessment of major bleeding, thromboembolic events, and cardiovascular mortality at follow-up; subgroup analysis for dialysis patients.
Main Results:
- 33 Hispanic patients were included; 27 had a mean follow-up of 12.4 months.
- Median age 70 years, 58% female; high median CHADS2 (3) and HAS-BLED (4) scores indicated high risk.
- 90-day mortality 3.7%; rates per 100 patient-years: cardioembolism 10.8, major bleeding 14.4. Comparable outcomes for dialysis patients.
Conclusions:
- LAAC is safe and feasible for reducing thromboembolic risk in a high-risk, multimorbid Hispanic population.
- The procedure demonstrates viability in patients with end-stage renal disease on dialysis.
- Findings support LAAC as an alternative stroke prevention strategy in underrepresented NVAF populations.
Abstract:
Background Left atrial appendage closure (LAAC) has emerged as an alternative approach for mitigating thrombotic risk in nonvalvular atrial fibrillation patients. However, existing registries often lack representation of the Hispanic population, motivating this study to elucidate the demographic, clinical, and procedural characteristics, specifically among Hispanic patients undergoing this procedure. Methods Adult patients who underwent percutaneous LAAC between June 2017 and July 2022 at a high-complexity hospital in Bogotá, COL, were included. Baseline and procedural characteristics are reported. For patients with available follow-up data, major bleeding, thromboembolic events, and cardiovascular mortality were assessed. A subgroup analysis was conducted for patients with end-stage renal disease on dialysis. Results We included 33 patients. Follow-up data were available for 27 patients, with a mean follow-up period of 12.4 months. The median age of the cohort was 70 years (SD 9), with 58% being women. The median CHADS2 and HAS-BLED scores were 3 points (IQR 2 to 4) and 4 points (IQR 3 to 4), respectively. The 90-day cardiovascular mortality rate was 3.7%, whereas cardioembolic episodes and major bleeding events were reported at rates of 10.8 and 14.4 per 100 patient years, respectively. The long-term outcomes of patients on dialysis were comparable to those of nondialysis patients. Conclusions Our study reinforces existing evidence supporting the safety of LAAC, particularly in a multimorbid patient population with elevated bleeding and thrombotic risks. In this high-risk cohort, LAAC emerges as a feasible alternative for reducing thromboembolic risk. Notably, patients on dialysis demonstrated comparable long-term outcomes, suggesting the procedure's viability in this subgroup as well.
More Related Videos
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Regurgitation I: Introduction
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

